AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26519119 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise
Number of subjects: 60
Study 26519119 — intervention group
Group type: COMPARATOR
Intervention: Combined exercise prescription
Number of subjects: 60
Study 25526360 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous kyphoplasty (PKP) with routine biopsy of every operated vertebral level (biopsy group)
Number of subjects: 196
Study 25526360 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous kyphoplasty (PKP) without biopsy (control group)
Number of subjects: 196
Study 22484341 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive‐behavioral therapy for insomnia and osteoarthritis pain (CBT‐PI)
Number of subjects: 367
Study 22484341 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive‐behavioral therapy for osteoarthritis pain alone (CBT‐P)
Number of subjects: 367
Study 22484341 — intervention group
Group type: COMPARATOR
Intervention: Education only control (EOC)
Number of subjects: 367
Study 20849619 — intervention group
Group type: EXPERIMENTAL
Intervention: Care as usual with the addition of occupational therapy
Number of subjects: 117
Study 20849619 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 117
Study 17990475 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral care via intermittent suction
Number of subjects: 36
Study 15847101 — intervention group
Group type: EXPERIMENTAL
Intervention: Artrofoon (8 tablets daily, n = 30)
Number of subjects: 60
Study 15847101 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (100 mg daily, n = 30)
Number of subjects: 60
Study 15847101 — intervention group
Group type: EXPERIMENTAL
Intervention: Artrofoon (4 tablets daily)
Number of subjects: 60
Study 11887515 — intervention group
Group type: EXPERIMENTAL
Intervention: New toothbrush
Number of subjects: 0
Study 11887515 — intervention group
Group type: COMPARATOR
Intervention: Worn toothbrush
Number of subjects: 0
Study 9785074 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 9487 1 mg kg‐1
Number of subjects: 0
Study 9785074 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 9487 2 mg kg‐1
Number of subjects: 0
Study 9785074 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 9487 3 mg kg‐1
Number of subjects: 0
Study 9785074 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 9785074 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 9487
Number of subjects: 0
Study 7615614 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I - Axial dynamisation (fixator unlocked at 4 to 6 weeks)
Number of subjects: 56
Study 7615614 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II - Spring fixator (unlocked at 4 to 6 weeks with a small silicone spring)
Number of subjects: 56
Study 7615614 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III - Spring fixator (unlocked from the start for cyclical micromovement)
Number of subjects: 56
Study 7615614 — intervention group
Group type: COMPARATOR
Intervention: Group I - Axial dynamisation
Number of subjects: 56
Study 7615614 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II - Spring fixator
Number of subjects: 56
Study 7615614 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III - Spring fixator with cyclical micromovement
Number of subjects: 56
Study 2384819 — intervention group
Group type: EXPERIMENTAL
Intervention: Gated blood pool scintigraphy
Number of subjects: 20
Study 2384819 — intervention group
Group type: COMPARATOR
Intervention: Inter-observer variability assessment
Number of subjects: 20
Study 364364 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole 225 mg/day and acetylsalicylic acid 1 gm/day
Number of subjects: 132
Study 364364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 364364 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence
Number of subjects: 132
Study 364364 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 132
Study 30615007 — intervention group
Group type: EXPERIMENTAL
Intervention: Momentary Failure (MF)
Number of subjects: 12
Study 30983008 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemoimmunotherapy
Number of subjects: 228
Study 30983008 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant (ASCT)
Number of subjects: 228
Study 30983008 — intervention group
Group type: EXPERIMENTAL
Intervention: BEAM conditioning regimen
Number of subjects: 228
Study 30983008 — intervention group
Group type: COMPARATOR
Intervention: Busulfan and melphalan (BuMel) conditioning regimen
Number of subjects: 228
Study 28083842 — intervention group
Group type: EXPERIMENTAL
Intervention: VPZ 20 mg once daily for 3 weeks
Number of subjects: 60
Study 28083842 — intervention group
Group type: EXPERIMENTAL
Intervention: LPZ 30 mg once daily for 3 weeks
Number of subjects: 60
Study 28083842 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 25827645 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 48
Study 25827645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 22888813 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent instrumental social support
Number of subjects: 1421
Study 22888813 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent emotional social support
Number of subjects: 1421
Study 22888813 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy (SE)
Number of subjects: 1421
Study 22046271 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation
Number of subjects: 249
Study 22046271 — intervention group
Group type: EXPERIMENTAL
Intervention: House-dust mite avoidance
Number of subjects: 249
Study 19445938 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance measured by HOMA2-IR
Number of subjects: 985
Study 19445938 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of steatosis on baseline biopsy
Number of subjects: 985
Study 19445938 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Mallory bodies
Number of subjects: 985
Study 19445938 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant weight change of >or=5% in the first year after randomization
Number of subjects: 985
Study 16768836 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg supplemental Zn per day
Number of subjects: 48
Study 16768836 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg supplemental Zn per day
Number of subjects: 48
Study 16768836 — intervention group
Group type: COMPARATOR
Intervention: 0 mg supplemental Zn per day (placebo)
Number of subjects: 48
Study 14695850 — intervention group
Group type: EXPERIMENTAL
Intervention: Purine analogs alone or in combination with alkylating agents and monoclonal antibodies
Number of subjects: 0
Study 14695850 — intervention group
Group type: COMPARATOR
Intervention: Alkylating agent-based therapy
Number of subjects: 0
Study 11323555 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg.kg‐1 of body mass)
Number of subjects: 16
Study 11323555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9460568 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Specialist Anticoagulant Service (NSAS)
Number of subjects: 0
Study 9460568 — intervention group
Group type: COMPARATOR
Intervention: Consultant Anticoagulant Service (CAS)
Number of subjects: 0
Study 7943793 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (70 micrograms.kg‐1.min‐1 i.v.)
Number of subjects: 9
Study 7943793 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.1 mg/kg i.v.)
Number of subjects: 9
Study 7943793 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.1 mg/kg i.v.)
Number of subjects: 9
Study 7943793 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine + Morphine
Number of subjects: 9
Study 7943793 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine + Ketamine
Number of subjects: 9
Study 7943793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3145269 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenethicillin
Number of subjects: 0
Study 3145269 — intervention group
Group type: EXPERIMENTAL
Intervention: Co‐trimoxazole
Number of subjects: 0
Study 3145269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 0
Study 3145269 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 0
Study 3145269 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial agents (general)
Number of subjects: 0
Study 3145269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor, co‐trimoxazole, doxycycline
Number of subjects: 0
Study 31980499 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg
Number of subjects: 48
Study 31980499 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg
Number of subjects: 48
Study 31980499 — intervention group
Group type: COMPARATOR
Intervention: Nonpregnant women with T2DM (Control)
Number of subjects: 48
Study 31980499 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (both doses)
Number of subjects: 48
Study 31980499 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg and 1000 mg)
Number of subjects: 48
Study 27883233 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin application
Number of subjects: 0
Study 27883233 — intervention group
Group type: COMPARATOR
Intervention: Placebo application
Number of subjects: 0
Study 27883233 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no application)
Number of subjects: 0
Study 25953832 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal scopolamine (0.4 mg)
Number of subjects: 19
Study 25953832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 24334216 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexunzipped interactive intervention website
Number of subjects: 2036
Study 24334216 — intervention group
Group type: COMPARATOR
Intervention: Information-only control website
Number of subjects: 2036
Study 24334216 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher value compensation (£20/US$32)
Number of subjects: 2036
Study 24334216 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower value compensation (£10/US$16)
Number of subjects: 2036
Study 21317165 — intervention group
Group type: EXPERIMENTAL
Intervention: MP4OX
Number of subjects: 474
Study 21317165 — intervention group
Group type: COMPARATOR
Intervention: HES (hydroxyethyl starch)
Number of subjects: 474
Study 18835434 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week group-based cognitive behavioral stress management (CBSM) intervention
Number of subjects: 128
Study 18835434 — intervention group
Group type: COMPARATOR
Intervention: 1-day psychoeducational control group
Number of subjects: 128
Study 17145651 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of isoflavones, lignans and Cimicifuga racemosa (group A, n = 40)
Number of subjects: 80
Study 17145651 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplements (group B, n = 40)
Number of subjects: 80
Study 14718406 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected patients
Number of subjects: 68
Study 14718406 — intervention group
Group type: COMPARATOR
Intervention: Control patients (non-HIV)
Number of subjects: 68
Study 14718406 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected patients undergoing percutaneous coronary intervention
Number of subjects: 68
Study 14718406 — intervention group
Group type: COMPARATOR
Intervention: Control patients undergoing percutaneous coronary intervention
Number of subjects: 68
Study 11760165 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction treatment (3 million units daily for the first 14 days, then 3 times per week)
Number of subjects: 31
Study 11760165 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (3 million units 3 times per week throughout)
Number of subjects: 31
Study 9268221 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiqueside (1, 2, and 3 g daily, b.i.d.)
Number of subjects: 39
Study 9268221 — intervention group
Group type: COMPARATOR
Intervention: Tiqueside (2 or 4 g/day, once daily)
Number of subjects: 39
Study 9268221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 8359182 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) 0.4 mg
Number of subjects: 12
Study 8359182 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) 0.8 mg
Number of subjects: 12
Study 8359182 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN)
Number of subjects: 12
Study 3458681 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel
Number of subjects: 10
Study 3458681 — intervention group
Group type: COMPARATOR
Intervention: Gel alone
Number of subjects: 10
Study 28846469 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% SDF applied annually (every 12 months)
Number of subjects: 888
Study 28846469 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% SDF applied semiannually (every 6 months)
Number of subjects: 888
Study 28846469 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% SDF applied annually (every 12 months)
Number of subjects: 888
Study 28846469 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% SDF applied semiannually (every 6 months)
Number of subjects: 888
Study 28846469 — intervention group
Group type: COMPARATOR
Intervention: 38% SDF
Number of subjects: 888
Study 28846469 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual SDF application with higher VPI score
Number of subjects: 888
Study 26374745 — intervention group
Group type: EXPERIMENTAL
Intervention: TT-173
Number of subjects: 0
Study 26374745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23434921 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (EACA)
Number of subjects: 26
Study 23434921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 21988715 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetil salicylic acid (ASA) 100 mg daily until third month of pregnancy
Number of subjects: 167
Study 21988715 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular-weight heparin (LMWH) - enoxaparine 40 mg daily until third month of pregnancy
Number of subjects: 167
Study 21988715 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA 100 mg plus LMWH 40 mg daily until third month of pregnancy
Number of subjects: 167
Study 21988715 — intervention group
Group type: COMPARATOR
Intervention: ASA 100 mg daily until third month of pregnancy
Number of subjects: 167
Study 19804570 — intervention group
Group type: EXPERIMENTAL
Intervention: SPO (Spectra Optia)
Number of subjects: 20
Study 19804570 — intervention group
Group type: COMPARATOR
Intervention: CSP (COBE Spectra)
Number of subjects: 20
Study 17963864 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 37
Study 17963864 — intervention group
Group type: COMPARATOR
Intervention: Laminaria
Number of subjects: 37
Study 15905896 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 min treadmill walk (50% VO(2) peak)
Number of subjects: 18
Study 15905896 — intervention group
Group type: COMPARATOR
Intervention: Control days
Number of subjects: 18
Study 12325052 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-oriented care intervention
Number of subjects: 151
Study 12325052 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 151
Study 10776982 — intervention group
Group type: EXPERIMENTAL
Intervention: GRADEX (granisetron 3 mg i.v. + dexamethasone 20 mg i.v.)
Number of subjects: 89
Study 10776982 — intervention group
Group type: EXPERIMENTAL
Intervention: TRODEX (tropisetron 5 mg i.v. + dexamethasone 20 mg i.v.)
Number of subjects: 89
Study 10776982 — intervention group
Group type: EXPERIMENTAL
Intervention: ONDEX (ondansetron 8 mg i.v. + dexamethasone 20 mg i.v. followed by ondansetron 8 mg p.o. x 2)
Number of subjects: 89
Study 10776982 — intervention group
Group type: EXPERIMENTAL
Intervention: GRADEX (first cycle)
Number of subjects: 89
Study 10776982 — intervention group
Group type: EXPERIMENTAL
Intervention: TRODEX (first cycle)
Number of subjects: 89
Study 10776982 — intervention group
Group type: EXPERIMENTAL
Intervention: ONDEX (first cycle)
Number of subjects: 89
Study 10776982 — intervention group
Group type: COMPARATOR
Intervention: GRADEX vs TRODEX
Number of subjects: 89
Study 8733437 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 7.5 mg/week
Number of subjects: 40
Study 8733437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8733437 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MTX and placebo)
Number of subjects: 40
Study 1348986 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 120
Study 1348986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 4016545 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin treatment (5000 units twice daily subcutaneously)
Number of subjects: 176
Study 4016545 — intervention group
Group type: COMPARATOR
Intervention: Low-dose heparin treatment supplemented with graded compression stockings
Number of subjects: 176
Study 31391683 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin-assisted collagen cross-linking (C3R)
Number of subjects: 78
Study 29748993 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Crisis Response Plan (S-CRP)
Number of subjects: 97
Study 29748993 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Crisis Response Plan (E-CRP)
Number of subjects: 97
Study 29748993 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 97
Study 27958220 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine ER plus Tamsulosin
Number of subjects: 152
Study 27958220 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine ER alone
Number of subjects: 152
Study 21887807 — intervention group
Group type: EXPERIMENTAL
Intervention: EstroG-100
Number of subjects: 64
Study 21887807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 20175014 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports training (8 hours a week)
Number of subjects: 463
Study 20175014 — intervention group
Group type: COMPARATOR
Intervention: Normotensive control group (no intervention)
Number of subjects: 463
Study 17687276 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg single-dose intravenous parecoxib
Number of subjects: 37
Study 15642078 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 308
Study 15642078 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 308
Study 12650956 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 300 mg/day
Number of subjects: 490
Study 12650956 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 40 mg/day
Number of subjects: 490
Study 12650956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 490
Study 12650956 — intervention group
Group type: COMPARATOR
Intervention: Pindolol
Number of subjects: 490
Study 10319772 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with bupivacaine and fentanyl
Number of subjects: 715
Study 10319772 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia with meperidine
Number of subjects: 715
Study 10319772 — intervention group
Group type: EXPERIMENTAL
Intervention: Nulliparity
Number of subjects: 715
Study 10319772 — intervention group
Group type: EXPERIMENTAL
Intervention: Labor longer than 12 hours
Number of subjects: 715
Study 8991563 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP breathing (10 cm H20)
Number of subjects: 10
Study 8991563 — intervention group
Group type: COMPARATOR
Intervention: BiPAP breathing (10/4 cm H20)
Number of subjects: 10
Study 31268268 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic positive airway pressure (BPAP) applied for 3 days postoperatively
Number of subjects: 35
Study 31268268 — intervention group
Group type: COMPARATOR
Intervention: Sham biphasic positive airway pressure (sham BPAP) applied for 3 days postoperatively
Number of subjects: 35
Study 28726481 — intervention group
Group type: EXPERIMENTAL
Intervention: Trainer-led BA training
Number of subjects: 77
Study 28726481 — intervention group
Group type: COMPARATOR
Intervention: Self-paced BA training
Number of subjects: 77
Study 24894079 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) with innovative negative pressure device (NPD)
Number of subjects: 48
Study 24894079 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods of dressing
Number of subjects: 48
Study 24442678 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual-reality training on a nephrectomy module
Number of subjects: 28
Study 24442678 — intervention group
Group type: COMPARATOR
Intervention: Traditional black-box simulator training
Number of subjects: 28
Study 22563244 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 24
Study 22563244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 19189676 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive application (Scotchbond Multi‐Purpose Plus)
Number of subjects: 20
Study 19189676 — intervention group
Group type: COMPARATOR
Intervention: No adhesive
Number of subjects: 20
Study 16162997 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg BID for 7 days
Number of subjects: 29
Study 16162997 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 29
Study 16162997 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 1000 mg QD for 7 days
Number of subjects: 29
Study 12663272 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized cocoa butter
Number of subjects: 17
Study 12663272 — intervention group
Group type: COMPARATOR
Intervention: Cocoa butter (control)
Number of subjects: 17
Study 10966246 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg bolus plus 2 microg/kg/hr infusion for 4 hours)
Number of subjects: 9
Study 8635728 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopic guidance during Maloney dilation
Number of subjects: 83
Study 8635728 — intervention group
Group type: COMPARATOR
Intervention: Blinded technique during Maloney dilation
Number of subjects: 83
Study 1463176 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia with propofol
Number of subjects: 50